Cannabinoids protected nerve cells from chemotherapy damage in lab tests | Research

The takeaway

Both synthetic and plant-derived cannabinoids preserved neuron viability (70-89% vs. 40% with chemo alone) and reduced axonal shortening from paclitaxel in cultured nerve cells.

People interested in cannabinoids for preventing chemotherapy side effects, particularly nerve damage.

70-89% neuron survival with cannabinoids vs. 40% with chemo alone

What the researchers found

When combined with paclitaxel, cannabinoids maintained cell viability at 70-89% compared to 40% with chemotherapy alone at 48 hours. Cannabinoids also preserved neurite length: paclitaxel alone shortened axons by 63%, while cannabinoid combinations limited shortening to 23-44%. Both synthetic (JWH-007, AM-694, MAB-CHMINACA) and phytocannabinoid preparations showed protective effects.

Why it matters

Chemotherapy-induced peripheral neuropathy affects 68% of paclitaxel patients and has no approved preventive treatment. If cannabinoids can protect nerves from chemo damage while maintaining cancer treatment, this could address a major unmet need in oncology.

The numbers in context

Cell viability with cannabinoids + chemo: 70-89% vs. 40% chemo alone at 48 hours. Axon shortening: 23-44% with cannabinoid combination vs. 63% with paclitaxel alone. Both synthetic and plant-derived cannabinoids effective.

How the study worked

In vitro study using primary dorsal root ganglion neuron cultures. Cell viability assessed with multiple cannabinoids at various doses and timepoints. Neurite outgrowth measured to assess neuroprotection against paclitaxel-induced peripheral neuropathy.

What this study cannot tell us

In vitro study only; nerve cells in culture do not replicate the complexity of neuropathy in a living body. Cannot determine if cannabinoids would also protect cancer cells from chemotherapy. Optimal doses and timing for clinical use are unknown.

How to read the evidence

Preliminary in vitro study with consistent neuroprotective findings across multiple cannabinoid types. Clinical translation requires animal studies and human trials.

When this study was published

Published in 2024 in Frontiers in Pharmacology.

The bigger picture

CIPN is one of the most common reasons cancer patients reduce or discontinue chemotherapy. A neuroprotective agent that does not interfere with anti-cancer effects would be a significant advance, and cannabinoids are candidates worth pursuing based on these preliminary data.

Questions still open

Do cannabinoids protect cancer cells from chemotherapy at the same doses that protect neurons? Which specific cannabinoid formulation would be most effective and safe in cancer patients? Would in vivo animal models confirm these neuroprotective effects?

Common questions

Can cannabinoids prevent chemo-related nerve damage?

In this lab study, both plant-derived and synthetic cannabinoids protected nerve cells from paclitaxel damage, maintaining viability at 70-89% compared to 40% without cannabinoids. Human studies are needed to confirm this.

Would cannabinoids interfere with chemotherapy?

This study focused on nerve protection and did not test whether cannabinoids also protect cancer cells. That question must be answered before clinical use.

Read the original research

The potential neuroprotective effects of cannabinoids against paclitaxel-induced peripheral neuropathy: in vitro study on neurite outgrowth.

Frontiers in pharmacology, 15, 1395951

View on PubMed ↗Publisher’s paper ↗

Citation

Creanga-Murariu, Ioana; Filipiuc, Leontina-Elena; Gogu, Maria-Raluca; Ciorpac, Mitica; Cumpat, Carmen Marinela; Tamba, Bogdan-Ionel; Alexa-Stratulat, Teodora. (2024). The potential neuroprotective effects of cannabinoids against paclitaxel-induced peripheral neuropathy: in vitro study on neurite outgrowth.. Frontiers in pharmacology, 15, 1395951. https://doi.org/10.3389/fphar.2024.1395951